Under the terms of the asset purchase agreement, AbCellera acquires full rights to the OrthoMab platform and Dualogics retains rights to develop existing internal assets and to complete existing partnership programs.
Lead Product(s): IgG-like bispecific antibodies
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 20, 2020